Grünenthal GmbH, a global, science-based pharmaceutical company and Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company, have completed a deal to enter into a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio.

The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide.

Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

As part of the joint venture, a new enterprise has been created to market Kyowa Kirin International’s established medicines portfolio, which comprises 13 brands across six therapeutic areas. The enterprise will be branded in all markets as Grünenthal Meds.

“Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain,” said Gabriel Baertschi, CEO, Grünenthal.

“The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this joint venture collaboration a reality,” said Jeremy Morgan, president, Kyowa Kirin International.